Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IxCell human umbilical cord mesenchymal stem cells
- Development stage
- Phase 1
- Lead developer
- iXCells Biotechnologies
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous, Intraarticular
01
Overview
IxCell human umbilical cord mesenchymal stem cells are an allogeneic, umbilical cord-derived mesenchymal stem cell (UC-MSC) therapy developed by IxCell Biotechnology. These cells are characterized by their high proliferative capacity, low immunogenicity, and potent immunomodulatory properties. Upon administration, the cells migrate to sites of injury or inflammation where they exert therapeutic effects primarily through paracrine signaling. They secrete a variety of bioactive molecules, including anti-inflammatory cytokines, growth factors, and extracellular vesicles, which modulate the activity of various immune cells such as T-cells, B-cells, and macrophages. This immunomodulatory action helps to dampen systemic or localized inflammation while promoting an environment conducive to endogenous tissue repair and regeneration. The product is currently under clinical investigation for various indications, including knee osteoarthritis, COVID-19-associated pneumonia, and liver cirrhosis.
- Brand names
- IxCell
- Other names
- IxCell hUC-MSCsIxCell human umbilical cord-derived mesenchymal stem cellsIxCell UC-MSCs
Beyond the preview
Go deeper on IxCell human umbilical cord mesenchymal stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IxCell human umbilical cord mesenchymal stem cells.